US 11559583
Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer
granted A61KA61K2039/507A61K47/6851
Quick answer
US patent 11559583 (Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer) held by Five Prime Therapeutics, Inc. expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K2039/507, A61K47/6851, A61K47/6879, A61K51/1084